secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001104659-23-002078
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aziyo Biologics reports record annual net sales of ~$49M, Q4 up 15-17% YoY
--------------------------------------------------------------------------

- Preliminary Q4 2022 net sales of ~$12.5-12.7M, up 15-17% vs Q4 2021.
- Full year 2022 record net sales of ~$49.0-49.2M, up 3-4% YoY; up ~15-16% excluding $4.9M discontinued product.
- SimpliDerm and CanGaroo combined Q4 net sales expected to grow ~30% vs Q4 2021.
- Company raised $15.2M in gross proceeds from recent financings; awaits FDA clearance for CanGaroo RM.
- CEO cites strong team performance; full Q4 and FY results expected in early March 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465923002078/0001104659-23-002078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465923002078/tm232674d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-002078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer